Clinical Trials Directory

Trials / Unknown

UnknownNCT02275221

Immune Response in Patients With Hepatitis B and C Infection

Investigation and Elucidation of Host Immune Responses in Patients With Hepatitic B and C Virus Infection

Status
Unknown
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
Mid and South Essex NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Using peripheral blood mononuclear cells (PBMC) and serum collection from HBV and HCV infected patients in a number of different immunological assays, the investigators hope to identify any changes in the number and function of these immune cells and to investigate how these changes contribute to viral persistence and disease progression.

Detailed description

Hepatitis B virus (HBV) and C (HCV) are the leading causes of liver disease worldwide. Approximately 400 million people worldwide are chronically infected with HBV world wide and it is estimated that 3% of the entire world population is infected with HCV and yet there is still no vaccine available. Chronic viral hepatitis infection is primarily the result of a complex interaction between the virus and an impaired host immune response. The host immune response has a unique role in HBV and HCV infection because it contributes not only to viral control clinical recovery and protective immunity but also to the development of chronic hepatitis and liver cirrhosis. There is currently no cure for most patients who already have chronic HBV and HCV infection and a proportion of patients fail to respond to current antiviral regimens. Since these patient remain at risk for disease progression it is crucial to investigate host immune responses and to determine the precise role of these responses in disease outcome. Using peripheral blood mononuclear cells (PBMC) and serum collection from HBV and HCV infected patients in a number of different immunological assays, we hope to identify any changes in the number and function of these immune cells and to investigate how these changes contribute to viral persistence and disease progression. This information can be utilised to develop more effective treatment regimens in order to reduce the current global burden of these diseases.

Conditions

Timeline

Start date
2013-08-01
Primary completion
2024-12-01
Completion
2024-12-01
First posted
2014-10-27
Last updated
2024-01-12

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02275221. Inclusion in this directory is not an endorsement.